search
Back to results

Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery (PENGUIN)

Primary Purpose

Infection, Pneumonia, Surgical Site Infection

Status
Recruiting
Phase
Phase 3
Locations
South Africa
Study Type
Interventional
Intervention
Chlorhexidine mouthwash
Oxygen
Oxygen
Sponsored by
University of Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infection

Eligibility Criteria

10 Years - 100 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults and children aged 10 years or over
  • Elective or emergency abdominal surgery via midline laparotomy with an anticipated abdominal incision of at least 5cm in length
  • Written informed consent of patient (signature or a fingerprint)

Exclusion Criteria:

  • Patients undergoing caesarean section
  • Patients with a documented or suspected allergy to chlorhexidine
  • Patient unable to complete postoperative follow-up (not contactable after discharge)
  • Previous enrolment in PENGUIN within the past 30 days
  • American Society of Anesthesiologists (ASA) grade V patients (expected to die with or without surgery)

Sites / Locations

  • Groote Schuur HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Experimental

Active Comparator

Arm Label

Mouthwash and liberal oxygen during surgery

No mouthwash and liberal oxygen during surgery

Mouthwash and restrictive oxygen during surgery

No mouthwash and restrictive oxygen during surgery

Arm Description

Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 80-100% FiO2 during surgery.

No pre-surgical mouthwash in combination with 80-100% FiO2 during surgery.

Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 21-30% FiO2 during surgery.

No pre-surgical mouthwash in combination with 21-30% FiO2 during surgery.

Outcomes

Primary Outcome Measures

Number of participants with pneumonia using the US Centers for Disease Control (CDC) definition of pneumonia (Mouthwash intervention only)
Pneumonia will be classified using the US Centers for Disease Control (CDC) definition of pneumonia
Number of participants with surgical site infection (Oxygen therapy intervention only)
The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision AND The patient must have at least one of the following: Purulent drainage from the wound Organisms are detected from a wound swab Wound opened spontaneously or by a clinician AND, fever (>38°C), OR at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; Diagnosis of SSI by a clinician or radiological imaging

Secondary Outcome Measures

Number of trial participant moralities (Mouthwash and oxygen therapy intervention comparisons)
Patient mortality status
Number of participants who received repeat abdominal surgery to treat complications (Oxygen therapy intervention only)
Repeat abdominal surgery to treat complications
Number of participants who received repeat abdominal surgery (Mouthwash and oxygen therapy interventions)
Repeat abdominal surgery
Length of hospital stay for index admission (Mouthwash and oxygen therapy interventions)
Length of hospital stay for index admission will be collected and will measure time from surgery to time of discharge.
Number of participants returning to normal activities (Mouthwash and oxygen therapy interventions)
Return to normal activities (e.g. work, school, or family duties) ascertained by trial specific case report forms.
Number of participants admissions to a critical care unit (Mouthwash and oxygen therapy interventions)
Admission to a critical care unit will be captured on the trial case report forms.
Health resource usage per patient
Resource use data will be collected as part of the economic evaluation of the different treatment combinations in a sub-group of adult patients at selected centers. Information related to post-operative cost (medicinal products, amenities and personal) will be collected on a health resource usage case report form designed by the trials health economist.

Full Information

First Posted
January 31, 2020
Last Updated
November 23, 2020
Sponsor
University of Birmingham
search

1. Study Identification

Unique Protocol Identification Number
NCT04256798
Brief Title
Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery
Acronym
PENGUIN
Official Title
PErioperative Respiratory Care and Outcomes for patieNts Undergoing hIgh Risk abdomiNal Surgery: A 2x2 Factorial, International Pragmatic Randomised Controlled Trial Across Low and Middle-income Countries
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Recruiting
Study Start Date
November 13, 2020 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
June 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Birmingham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
PENGUIN is a pragmatic multi-center trial investigating the effects of pre-operative mouthwash and perioperative oxygen on the incidences of pneumonia and surgical site infection (SSI) following major abdominal surgery. Patients will be recruited from low and middle income countries and randomly assigned to a trial treatment arms: a) pre-operative chlorhexidine mouthwash and 80-100% FiO2; b) no pre-operative mouthwash and 80-100% fraction of inspired oxygen (FiO2); c) pre-operative chlorhexidine mouthwash and 21- 30% FiO2; or d) no pre-operative mouthwash and 21-30% FiO2.
Detailed Description
PENGUIN is a pragmatic, blinded (outcome assessor), 2x2 factorial, multi-centre randomised controlled trial, with an internal pilot, to evaluate measures to reduce surgical site infection (SSI) and pneumonia rates in patients undergoing surgery with an abdominal incision. Pneumonia is one of the most serious complications to occur after surgery, accounting for up to one in four of all postoperative deaths. The incidence is greater still in high-risk populations such as those undergoing midline laparotomy where mortality rates are more than 10%. SSIs are clearly important being the most frequent healthcare-associated infection in LMICs, affecting one in three patients undergoing contaminated or dirty surgery (34, 35). SSIs cause pain, discomfort and disability. They increase the time taken to return to work, and healthcare costs The risk of postoperative mortality and complications such as surgical site infection is three times greater in low and middle-income countries (LMICs) than in high-income countries. In order to address surgical need worldwide, it is estimated that provision of a further 312 million operations would be required each year. Patients will be recruited from hospitals in Low and Middle Income Countries (LMICs) who are undergoing elective or emergency mid-line laparotomy. Eligible patients will be randomised at the level of the individual in a 1:1:1:1 ratio between: A. Preoperative chlorhexidine mouthwash and 80-100% FiO2 during surgery B. No preoperative chlorhexidine mouthwash and 80-100% FiO2 during surgery C. Preoperative chlorhexidine mouthwash and 21-30% FiO2 during surgery D. No preoperative chlorhexidine mouthwash and 21-30% FiO2 during surgery The 6 month internal pilot will assess the feasibility of recruitment, compliance with treatment allocation and patient retention and follow-up rates. The main Randomised Control Trial will recruit 12,924 participants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection, Pneumonia, Surgical Site Infection, Wound Infection, Surgical Wound Infection, Postoperative Complications, Anesthesia, Communicable Disease, Pathologic Processes, Perioperative Complication, Chlorhexidine, Laparotomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
12942 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Mouthwash and liberal oxygen during surgery
Arm Type
Experimental
Arm Description
Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 80-100% FiO2 during surgery.
Arm Title
No mouthwash and liberal oxygen during surgery
Arm Type
Active Comparator
Arm Description
No pre-surgical mouthwash in combination with 80-100% FiO2 during surgery.
Arm Title
Mouthwash and restrictive oxygen during surgery
Arm Type
Experimental
Arm Description
Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 21-30% FiO2 during surgery.
Arm Title
No mouthwash and restrictive oxygen during surgery
Arm Type
Active Comparator
Arm Description
No pre-surgical mouthwash in combination with 21-30% FiO2 during surgery.
Intervention Type
Drug
Intervention Name(s)
Chlorhexidine mouthwash
Intervention Description
0.2% Chlorhexidine digluconate
Intervention Type
Drug
Intervention Name(s)
Oxygen
Intervention Description
Oxygen 80-100%
Intervention Type
Drug
Intervention Name(s)
Oxygen
Intervention Description
Oxygen 21-30 %
Primary Outcome Measure Information:
Title
Number of participants with pneumonia using the US Centers for Disease Control (CDC) definition of pneumonia (Mouthwash intervention only)
Description
Pneumonia will be classified using the US Centers for Disease Control (CDC) definition of pneumonia
Time Frame
Within 30 days post-surgery from index operation
Title
Number of participants with surgical site infection (Oxygen therapy intervention only)
Description
The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision AND The patient must have at least one of the following: Purulent drainage from the wound Organisms are detected from a wound swab Wound opened spontaneously or by a clinician AND, fever (>38°C), OR at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; Diagnosis of SSI by a clinician or radiological imaging
Time Frame
Within 30 days post-surgery from index operation
Secondary Outcome Measure Information:
Title
Number of trial participant moralities (Mouthwash and oxygen therapy intervention comparisons)
Description
Patient mortality status
Time Frame
Within 30 days post-surgery from index operation
Title
Number of participants who received repeat abdominal surgery to treat complications (Oxygen therapy intervention only)
Description
Repeat abdominal surgery to treat complications
Time Frame
Within 30 days post-surgery from index operation
Title
Number of participants who received repeat abdominal surgery (Mouthwash and oxygen therapy interventions)
Description
Repeat abdominal surgery
Time Frame
Within 30 days post-surgery from index operation
Title
Length of hospital stay for index admission (Mouthwash and oxygen therapy interventions)
Description
Length of hospital stay for index admission will be collected and will measure time from surgery to time of discharge.
Time Frame
Within 30-days post surgery from index operation
Title
Number of participants returning to normal activities (Mouthwash and oxygen therapy interventions)
Description
Return to normal activities (e.g. work, school, or family duties) ascertained by trial specific case report forms.
Time Frame
Within 30 days post-surgery from index operation
Title
Number of participants admissions to a critical care unit (Mouthwash and oxygen therapy interventions)
Description
Admission to a critical care unit will be captured on the trial case report forms.
Time Frame
Within 30 days post-surgery from index operation
Title
Health resource usage per patient
Description
Resource use data will be collected as part of the economic evaluation of the different treatment combinations in a sub-group of adult patients at selected centers. Information related to post-operative cost (medicinal products, amenities and personal) will be collected on a health resource usage case report form designed by the trials health economist.
Time Frame
Within 30 days post-surgery from index operation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults and children aged 10 years or over Elective or emergency abdominal surgery via midline laparotomy with an anticipated abdominal incision of at least 5cm in length Written informed consent of patient (signature or a fingerprint) Exclusion Criteria: Patients undergoing caesarean section Patients with a documented or suspected allergy to chlorhexidine Patient unable to complete postoperative follow-up (not contactable after discharge) Previous enrolment in PENGUIN within the past 30 days American Society of Anesthesiologists (ASA) grade V patients (expected to die with or without surgery)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Matthew Soden, BSc, PhD
Phone
0121 414 4762
Email
penguin@trials.bham.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Rachel Lillywhite, BA
Phone
0121 414 4762
Email
penguin@trials.bham.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rupert Pearse
Organizational Affiliation
Royal London Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Groote Schuur Hospital
City
Cape Town
ZIP/Postal Code
7925
Country
South Africa
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be shared via a process of controlled access
IPD Sharing Time Frame
6 months post publication
IPD Sharing Access Criteria
Formal requests must be submitted to the Data Access Group at Birmingham Clinical Trials Unit

Learn more about this trial

Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery

We'll reach out to this number within 24 hrs